Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 10, 2012, Pages 2149-2157

  Zhang, Y ^a   Ye, J ^a   Hu, L ^a   Zhang, S ^a   Zhang, S H ^a   Li, Y ^b   Kunapuli, S P ^c   Ding, Z ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inverse agonist; P2Y12; Platelet; Thrombosis; Transgenic mice

Indexed keywords

ANTITHROMBOCYTIC AGENT; ARC 69931MX; ARC 78511; CYCLIC AMP; PROTEIN KINASE B; PURINERGIC P2Y12 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; HEMOSTASIS; IN VIVO STUDY; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS;

ADENOSINE MONOPHOSPHATE; ANIMALS; BLEEDING TIME; BLOOD PLATELETS; CHLORIDES; CYCLIC AMP; DISEASE MODELS, ANIMAL; DRUG INVERSE AGONISM; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; GENOTYPE; MICE; MICE, TRANSGENIC; PHENOTYPE; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THROMBOSIS;

EID: 84866857618     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04894.x     Document Type: Article

References (31)

1. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-4.
2. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117: 2102-12.
3. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340-5.
4. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121: 171-9.
5. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF, Lefkowitz RJ. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature 1995; 374: 272-6.
6. Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996; 335: 1115-22.
7. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 2002; 360: 692-4.
8. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels Y. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 2011; 43: 1119-26.
9. Parma J, Duprez L, van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365: 649-51.
10. Biebermann H, Winkler F, Handke D, Teichmann A, Gerling B, Cameron F, Eichhorst J, Gruters A, Wiesner B, Kuhnen P, Krude H, Kleinau G. New pathogenic thyrotropin receptor mutations decipher differentiated activity switching at a conserved helix 6 motif of family A GPCR. J Clin Endocrinol Metab 2012; 97: E228-32.
11. Ignar DM, Goetz AS, Noble KN, Carballo LH, Stroup AE, Fisher JC, Boucheron JA, Brainard TA, Larkin AL, Epperly AH, Shearer TW, Sorensen SD, Speake JD, Hommel JD. Regulation of ingestive behaviors in the rat by GSK1521498, a novel {micro}-opioid receptor-selective inverse agonist. J Pharmacol Exp Ther 2011; 339: 24-34.
12. Ding Z, Kim S, Kunapuli SP. Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor. Mol Pharmacol 2006; 69: 338-45.
13. Nguyen HG, Yu G, Makitalo M, Yang D, Xie HX, Jones MR, Ravid K. Conditional overexpression of transgenes in megakaryocytes and platelets in vivo. Blood 2005; 106: 1559-64.
14. Weng Z, Li D, Zhang L, Chen J, Ruan C, Chen G, Gartner TK, Liu J. PTEN regulates collagen-induced platelet activation. Blood 2010; 116: 2579-81.
15. Ding Z, Bynagari YS, Mada SR, Jakubowski JA, Kunapuli SP. Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists. J Thromb Haemost 2009; 7: 232-4.
16. Shankar H, Murugappan S, Kim S, Jin J, Ding Z, Wickman K, Kunapuli SP. Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. Blood 2004; 104: 1335-43.
17. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003; 101: 3908-14.
18. Berlot CH. Expression and functional analysis of G protein alpha subunits in S49 lymphoma cells. Methods Enzymol 2002; 344: 261-77.
19. Banno F, Chauhan AK, Kokame K, Yang J, Miyata S, Wagner DD, Miyata T. The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood 2009; 113: 5323-9.
20. Hu L, Fan Z, Du H, Ni R, Zhang S, Yin K, Ye J, Zhang Y, Wei X, Zhang X, Gross PL, Kunapuli SP, Ding Z. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb Haemost 2011; 106: 1203-14.
21. Jin J, Tomlinson W, Kirk IP, Kim YB, Humphries RG, Kunapuli SP. The C6-2B glioma cell P2Y(AC) receptor is pharmacologically and molecularly identical to the platelet P2Y(12) receptor. Br J Pharmacol 2001; 133: 521-8.
22. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004; 279: 4186-95.
23. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-8.
24. Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406.
25. Adams JW, Ramirez J, Shi Y, Thomsen W, Frazer J, Morgan M, Edwards JE, Chen W, Teegarden BR, Xiong Y, Al-Shamma H, Behan DP, Connolly DT. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)ben zamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. J Pharmacol Exp Ther 2009; 331: 96-103.
26. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003; 108: 2971-3.
27. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
28. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, Sabeti S, Amighi J, Minar E, Brunner M, Muller M, Mannhalter C. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005; 36: 1394-9.
29. Rudez G, Pons D, Leebeek F, Monraats P, Schrevel M, Zwinderman A, de Winter R, Tio R, Doevendans P, Jukema W, de Maat M. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 2008; 29: 375-80.
30. Rudez G, Bouman HJ, van Werkum JW, Leebeek FW, Kruit A, Ruven HJ, ten Berg JM, de Maat MP, Hackeng CM. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet 2009; 2: 515-21.
31. Staritz P, Kurz K, Stoll M, Giannitsis E, Katus HA, Ivandic BT. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol 2009; 133: 341-5.